Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 43.84 USD -1.17% Market Closed
Market Cap: 3.5B USD

Veracyte Inc
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Veracyte Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Selling, General & Administrative
-$215.5m
CAGR 3-Years
-14%
CAGR 5-Years
-20%
CAGR 10-Years
-16%
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.8B
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7B
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$3.2B
CAGR 3-Years
-17%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

Veracyte Inc., founded in 2008, operates at the intriguing intersection of biotechnology and diagnostics, leveraging genomic insights to transform the landscape of disease diagnosis. The company's core mission is to improve the accuracy and efficiency of diagnostic testing, thus enabling better treatment decisions. Veracyte has woven innovation into its business model, creating a suite of genomic tests primarily for oncology and pulmonology. These tests are designed to resolve diagnostic ambiguity, particularly in cases where traditional tests might fall short. By harnessing advanced genomic technology, Veracyte empowers healthcare providers with definitive answers, thus facilitating timely and appropriate patient management. The company's revenue engine is driven by its extensive portfolio of products and services. At the heart of its operations is a series of diagnostic tests—such as Afirma for thyroid cancer, Percepta for lung cancer, and Envisia for idiopathic pulmonary fibrosis—each of which addresses key unmet medical needs. Veracyte generates income by selling these tests primarily to hospitals and healthcare providers, who in turn utilize the insights to bolster their clinical decision-making. Additionally, the company licenses its proprietary biobank and genomic platform to partners in research and pharma industries, unlocking further monetary streams. As payers increasingly recognize and reimburse the value of these precision diagnostic tools, Veracyte continues to strategically expand its market reach, reinforcing its role as a vital player in the biotech domain.

VCYT Intrinsic Value
23.49 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Veracyte Inc's Selling, General & Administrative?
Selling, General & Administrative
-215.5m USD

Based on the financial report for Sep 30, 2025, Veracyte Inc's Selling, General & Administrative amounts to -215.5m USD.

What is Veracyte Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-16%

Over the last year, the Selling, General & Administrative growth was -8%. The average annual Selling, General & Administrative growth rates for Veracyte Inc have been -14% over the past three years , -20% over the past five years , and -16% over the past ten years .

Back to Top